The protein in question is CD37, a member of the tetraspanin family. Tetraspanins are small four-pass transmembrane proteins that do not act as classical receptors themselves. Instead, they function as molecular organizers, clustering immune receptors into microdomains on the cell surface and fine-tuning the signals those receptors deliver. On leukocytes, CD37 has been implicated in B cell signaling, phagocytosis, and inflammatory regulation, but its role in ischemic tissue injury had remained largely unexplored. The NYU team began with a simple observation drawn from human tissue: in gastrocnemius muscle samples from patients with PAD, CD37 expression was markedly elevated, hinting that this immune organizer might be part of the disease process rather than a bystander.

To understand what that elevation meant, the researchers applied deconvolution-based immune profiling to transcriptomic data from human PAD muscle. This computational approach infers the composition of immune cell populations within bulk tissue gene expression data, allowing the team to link CD37 levels to specific immune programs. The results were striking. CD37 expression correlated strongly with overall immune infiltration, with a correlation coefficient of 0.51 and a p-value of 0.0002. More tellingly, its strongest relationship was with inflammatory macrophage programs, showing a correlation of 0.48 with a p-value of 0.0003. Macrophages, the tissue-resident scavenger cells capable of both fueling and resolving inflammation, appeared to be the cell type most tightly linked to CD37 abundance in failing human muscle.

Correlation alone cannot establish causation, so the team turned to an experimental system. They used the murine hindlimb ischemia model, a standard technique in which blood flow to a mouse’s hind leg is surgically interrupted, mimicking the ischemic injury of severe PAD. They then compared wild-type mice with genetically engineered mice lacking CD37 entirely, known as Cd37 knockout mice. Over the following weeks, the researchers measured perfusion recovery using laser-based blood flow imaging, examined skeletal muscle histology under the microscope, and profiled gene expression in the recovering tissue. The differences between the two groups were immediate and substantial.

The knockout mice revascularized far faster than their normal counterparts. By the key recovery timepoint, Cd37-deficient animals had achieved 87.6 percent reperfusion on average, compared with only 62.9 percent in wild-type mice, a difference that reached statistical significance at p less than 0.04. Blood flow, however, was only part of the story. When the researchers examined the muscle itself, they found that the knockout mice had rebuilt far more of their damaged tissue. Mature muscle fibers made up 77.9 percent of the recovered tissue in CD37-deficient animals versus just 46.7 percent in wild-type controls, with a p-value below 0.02. In other words, removing CD37 did not merely restore circulation; it allowed the muscle to genuinely regenerate rather than degenerate into scar tissue and fat.

To dissect the molecular mechanisms behind this accelerated healing, the team performed RNA sequencing on post-ischemic muscle from both groups. The analysis identified 594 differentially expressed genes at an adjusted p-value threshold of less than 0.05, a substantial transcriptional rewiring driven by the absence of a single surface protein. Pathway analysis revealed a coherent pattern. In the knockout muscle, genes related to muscle mass maintenance and collagen degradation were upregulated, suggesting active tissue rebuilding and clearance of fibrotic deposits. Conversely, pathways governing mitochondrial oxidative metabolism and proinflammatory signaling were downregulated. That the metabolic machinery of the muscle shifted away from oxidative programs may seem counterintuitive, but it likely reflects a reduced burden of inflammatory stress, which is known to distort mitochondrial function in ischemic tissue.

The most compelling findings emerged when the researchers integrated their RNA module scoring with immunohistochemistry, staining tissue sections to identify specific immune cell populations. This combined approach revealed that CD37 deficiency was associated with a fundamental reprogramming of macrophages toward a resolution phenotype. The knockout muscle contained macrophages with higher proresolving signatures and lower inflammatory signatures, and it harbored increased numbers of CD163-positive macrophages, a marker classically associated with anti-inflammatory, tissue-repairing macrophage states. In essence, the immune environment of the healing muscle had flipped from one that attacks damaged tissue to one that cleans up and rebuilds it.

To confirm that this shift originated in the macrophages themselves rather than being a secondary effect of the healthier tissue environment, the team isolated bone marrow-derived macrophages from both mouse groups and stimulated them ex vivo. Macrophages lacking CD37 secreted significantly lower levels of inflammatory cytokines and chemokines, the chemical messengers that recruit and activate additional immune cells and amplify tissue-damaging inflammation. This cell-autonomous result strengthens the causal chain: CD37 on macrophages directly promotes their inflammatory behavior, and that behavior, in turn, impairs the revascularization and regeneration of ischemic muscle.

The translational implications are considerable. Current therapies for chronic limb-threatening ischemia, including surgical bypass, angioplasty, and drug-eluting stents, address the plumbing of the disease but often leave the inflammatory biology untouched. Anti-inflammatory approaches to cardiovascular disease have gained momentum in recent years, but targeting inflammation broadly carries infection risks. CD37 offers something more precise: a surface molecule on immune cells whose removal shifts macrophages toward resolution without eliminating them. Notably, CD37 is already a validated target in oncology, with anti-CD37 antibody therapies in clinical development for B cell malignancies, which means the immunomodulatory toolkit for this protein is further along than for most novel targets. Repurposing or adapting those strategies for vascular medicine is a plausible next step, though the authors and outside observers alike would caution that a genetically engineered mouse is a long way from a diabetic patient with a non-healing foot ulcer.

There are also important caveats embedded in the data. The human findings are associative, drawn from transcriptomic correlations rather than direct functional experiments in patients. The mouse studies used complete knockout animals, so the effects of partial or transient CD37 inhibition remain unknown, as do potential consequences for the immune functions CD37 serves elsewhere, including B cell development and antitumor surveillance. The study was funded by the National Institutes of Health under grant R01HL167917 and by an American Heart Association postdoctoral fellowship, and the authors report no competing interests. Still, the convergence of human association, mouse genetics, transcriptomics, histology, and ex vivo cell biology makes a unusually coherent case. If future work confirms that blocking CD37 in patients with critical limb-threatening ischemia can tip their macrophages toward resolution, a protein once studied mainly by immunologists could become an unexpected lever for saving limbs, and the millions of people living with the silent narrowing of their leg arteries may finally gain a therapy that heals muscle, not just vessels.

Subject of Research: The role of the leukocyte tetraspanin CD37 in inflammation, revascularization, and skeletal muscle recovery in peripheral artery disease

Article Title: CD37 impairs revascularization and muscle recovery in peripheral artery disease

Article References: Dai, M., Gindri Dos Santos, B., Wu, J., Ferreira, E., Li, Z., Biswas, B., Schlamp, F., Boothman, I., & Barrett, T. J. (2026). CD37 impairs revascularization and muscle recovery in peripheral artery disease. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08799-3

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08799-3

Keywords: peripheral artery disease, CD37, tetraspanin, macrophages, inflammation, hindlimb ischemia, revascularization, muscle regeneration, critical limb-threatening ischemia, immune reprogramming, translational medicine, cytokines

Moyamoya vasculopathy is an umbrella term covering two related but distinct conditions. Moyamoya disease is a chronic, progressive narrowing of the terminal internal carotid arteries and the proximal segments of the anterior and middle cerebral arteries, accompanied by a hazy network of tiny collateral vessels at the base of the brain that resembles a puff of smoke on angiography, the meaning of the Japanese word moyamoya. Moyamoya syndrome, by contrast, produces a similar vascular picture but arises secondarily, most often when intracranial atherosclerosis mimics the appearance of the idiopathic disease. Distinguishing the two matters enormously, because their underlying biology, prognosis, and treatment strategies diverge, yet conventional angiography alone often cannot separate them reliably.

The research team, led by investigators at a major Chinese hospital registry, enrolled 398 consecutive adults with radiologically confirmed moyamoya vasculopathy between September 2017 and April 2025. Every patient underwent imaging on the same 3.0-Tesla MR scanner using a standardized protocol that included T1-weighted, T2-weighted, FLAIR, diffusion-weighted, and time-of-flight angiographic sequences, along with high-resolution vessel wall imaging. By scanning all participants on a single machine, the investigators eliminated the interscanner variability that often plagues multicenter imaging studies, allowing vessel wall measurements to be compared directly across the cohort.

High-resolution MRI has emerged in recent years as the decisive tool for separating the two etiologies. In moyamoya disease, the affected arteries typically show concentric, uniform wall thickening, a reduction in the outer diameter of the vessel, and negative or constrictive remodeling, meaning the artery wall shrinks inward as the disease progresses rather than expanding outward. Atherosclerosis-associated moyamoya vasculopathy displays the opposite signature: irregular, eccentric thickening caused by lipid-rich or hemorrhagic plaques, and positive or expansive remodeling, in which the vessel enlarges to accommodate plaque growth. Applying these criteria, the researchers classified 279 patients as having moyamoya disease and 61 as having the atherosclerosis-associated form.

The clinical profiles of the two groups differed in telling ways. Patients with moyamoya disease were more frequently female, consistent with the well-established female predominance of the idiopathic condition, and were significantly more likely to report a family history of early-onset stroke in first-degree relatives, a hallmark of the genetic predisposition linked to the RNF213 susceptibility gene. They also showed more frequent involvement of the posterior cerebral arteries, reflecting the diffuse, whole-circle-of-Willis nature of the disease. The atherosclerosis-associated group, though similar in age, lacked these familial and posterior-circulation signatures, reinforcing the view that it represents a secondary, plaque-driven process rather than a genetically driven arteriopathy.

To determine which imaging features actually tracked with stroke, the team took an unusually granular approach: they analyzed each cerebral hemisphere separately. Of the 558 hemispheres in the moyamoya disease group, 169 had suffered middle cerebral artery territory infarcts, visible as acute or chronic lesions on MRI, while 389 remained asymptomatic. Because the two hemispheres of the same patient are statistically correlated, the researchers used generalized estimating equations, a regression framework that treats each patient as a cluster, adjusting for age, sex, hypertension, diabetes, hyperlipidemia, smoking, alcohol use, and family history of early stroke. This design allowed each hemisphere to serve, in effect, as its own internal comparison.

The results in moyamoya disease were strikingly consistent. Ischemic hemispheres were independently associated with greater middle cerebral artery stenosis, more advanced Suzuki stage, and higher stenosis scores on the internal carotid, middle cerebral, and posterior cerebral arteries. The posterior cerebral artery score carried the strongest effect, with each one-point increase more than doubling the odds of ischemia. Intriguingly, the remodeling index of the middle cerebral artery showed the opposite relationship: hemispheres with more constrictive remodeling were more likely to be ischemic, suggesting that for a given degree of luminal narrowing, the inward shrinkage of the vessel wall compounds hemodynamic compromise, while better-preserved or compensating vessels maintain perfusion.

In the atherosclerosis-associated group, the picture inverted almost completely. Here, the degree of middle cerebral artery stenosis, the Suzuki stage, and the carotid and posterior circulation scores all lost their statistical significance after adjustment. What remained significant were the remodeling index of the middle cerebral artery, which was positively associated with ischemia, and involvement of the anterior cerebral artery. This pattern suggests that in plaque-driven moyamoya vasculopathy, it is not the raw percentage of narrowing that matters but how the vessel wall remodels around the plaque and whether the anterior circulation can still serve as a collateral pathway. Positive remodeling, long recognized as a marker of vulnerable atherosclerotic plaques, appears to signal danger rather than compensation in this group.

The authors are careful to frame these findings as cross-sectional associations rather than proven predictors of future stroke, noting that their definition of ischemic hemispheres included both acute and old infarcts, and that the retrospective, single-center design and the relatively small atherosclerotic subgroup impose limits on generalizability. They also acknowledge that a small fraction of patients lacked internal carotid artery involvement on angiography, a population that the revised 2022 diagnostic criteria would technically exclude, though sensitivity analyses excluding these patients left the results qualitatively unchanged. Even so, the hemisphere-level, cluster-adjusted analysis represents one of the most detailed noninvasive characterizations of moyamoya vasculopathy published to date.

The clinical implications are potentially far-reaching. For patients with moyamoya disease, quantitative measures such as stenosis severity, Suzuki stage, and combined arterial scores, together with evidence of constrictive remodeling, could help identify which hemisphere is at highest risk and guide the timing of revascularization surgery. For those with the atherosclerosis-associated form, attention should shift toward plaque behavior and anterior circulation collateral integrity rather than stenosis percentage alone, aligning management more closely with modern intracranial atherosclerosis care, where recent long-term evidence has questioned the value of stenting and pointed instead toward bypass options in selected cases. The study’s core lesson is that moyamoya vasculopathy is not one disease but two, and the artery wall itself, imaged at high resolution, tells clinicians which one they are treating.

Subject of Research: Etiology-specific associations between high-resolution MRI vessel wall features and cerebral infarction in adult moyamoya vasculopathy

Article Title: High‐Resolution MRI Revealed Different Etiology‐Specific Associations With Cerebral Infarction in Adult Moyamoya Vasculopathy

Article References: Han, G., Pan, J., Hong, Y., Fan, X., Yao, M., Zhou, L., Zhu, Y., Feng, F., & Ni, J. (2026). High‐Resolution MRI Revealed Different Etiology‐Specific Associations With Cerebral Infarction in Adult Moyamoya Vasculopathy. Annals of Clinical and Translational Neurology, 13(10), 2057-2067. https://doi.org/10.1002/acn3.70380

Image Credits: AI Generated

DOI: 10.1002/acn3.70380

Keywords: moyamoya disease, moyamoya vasculopathy, high-resolution MRI, vessel wall imaging, cerebral infarction, intracranial atherosclerosis, remodeling index, Suzuki stage, collateral circulation, stroke risk, RNF213, revascularization

The research team set out to identify the factors that influence sleep quality in the early postoperative period after complete revascularization. They recruited 186 patients with coronary heart disease who had undergone interventional therapy and assessed them with a battery of standardized psychological and clinical scales during an outpatient follow-up visit three months after their procedure. This three-month window is clinically meaningful. It is late enough that the acute discomfort of the intervention has passed, but early enough that patients are still adjusting to a new medication regimen, a revised sense of their own mortality, and the daily reality of living with a chronically diseased heart. Sleep disturbances arising in this period can shape long-term adherence to cardiac rehabilitation, medication, and lifestyle change.

When the researchers ran their statistical models, two psychological variables emerged as independent negative predictors of sleep quality. Anxiety, with an odds ratio of 0.86 and a P value of 0.023, and depression, with an odds ratio of 0.81 and a P value of 0.009, both significantly predicted worse sleep. In practical terms, the higher a patient scored on measures of anxiety or depression, the more likely they were to report poor sleep quality, even after accounting for other clinical characteristics. This finding alone would not surprise cardiologists or psychiatrists, who have long recognized that mood disturbances are common after acute cardiac events and interventions. What came next, however, was far less expected.

The team turned to the PROCESS macro, a widely used statistical tool for probing interactions and conditional effects, to ask whether β-blocker use modified the relationship between anxiety and sleep. β-Blockers are a cornerstone of post-intervention cardiac care. They blunt the effects of adrenaline on the heart, lowering heart rate and blood pressure, reducing myocardial oxygen demand, and improving survival in many patients with coronary disease. The patients in this study were predominantly taking metoprolol, a lipophilic β-blocker that readily crosses the blood-brain barrier, a property long suspected to underlie its effects on sleep, dreams, and central nervous system symptoms. What the analysis revealed was a statistically significant interaction between β-blocker use and anxiety on sleep quality, with an odds ratio of 1.39 and a P value of 0.045. In these patients, β-blockers significantly amplified the negative impact of anxiety on sleep.

That interaction, however, was not uniform across the patient population, and this is where the study becomes genuinely thought-provoking. When the researchers stratified their sample by metabolic and disease-severity variables, a clear pattern of heterogeneity emerged. In patients with preserved metabolic function, defined by a HOMA-IR score below 2.5, a standard index of insulin resistance calculated from fasting glucose and insulin levels, β-blockers significantly intensified the sleep-disrupting effect of anxiety, with an odds ratio of 0.61 and a P value of 0.017. The same held true for patients with mild coronary lesions, assessed using the Gensini score, a widely used angiographic grading system in which scores below 33 indicate limited coronary disease. In this milder-disease group, the interaction was again significant, with an odds ratio of 0.57 and a P value of 0.027.

Just as telling were the groups in which the interaction vanished entirely. Among patients with insulin resistance, those with severe coronary lesions, and those suffering from depression, the amplifying effect of β-blockers on the anxiety-sleep relationship was not observed. The authors interpret this asymmetry as a paradox: intact physiological function may actually increase susceptibility to drug-psychological interactions. One plausible reading is that patients whose metabolisms and coronary anatomy are relatively preserved have more physiological reserve to spare, so the subtle central nervous system effects of a lipophilic β-blocker are not masked by the heavier burden of metabolic dysfunction or advanced disease. In sicker patients, by contrast, the dominant drivers of poor sleep may be the illness itself, insulin resistance, and depression, leaving less detectable room for the drug-anxiety interplay to express itself.

The pharmacology behind this interaction deserves attention. Metoprolol, unlike hydrophilic β-blockers such as atenolol, penetrates the central nervous system efficiently, where it can interfere with noradrenergic signaling involved in arousal and sleep-wake regulation. Lipophilic β-blockers have been associated in earlier literature with nightmares, vivid dreams, and sleep fragmentation. Anxiety, for its part, is characterized by hyperarousal, elevated sympathetic tone, and intrusive worry, all of which are hostile to the initiation and maintenance of sleep. The new findings suggest these two forces do not merely add together; they multiply. A patient whose sympathetic nervous system is already revved by anxiety may be particularly vulnerable to a drug that alters central adrenergic processing, producing sleep disruption greater than either factor alone would predict.

The clinical implications are immediate and practical. The authors advise that clinicians should monitor sleep quality when prescribing lipophilic β-blockers to metabolically healthier patients with mild coronary lesions. In an era when β-blockers are prescribed almost reflexively after coronary intervention, this is a call for more nuanced prescribing. It does not mean these patients should stop their medication, which remains protective for the heart, but it does mean that a routine question about sleep at follow-up visits could identify a modifiable problem early. Switching to a hydrophilic agent, adjusting the timing of the dose, or treating the anxiety itself are all strategies that might be weighed against the sleep findings, though the study was observational and exploratory and cannot establish that such changes would improve outcomes.

The authors are appropriately cautious about the limits of their work. The study was cross-sectional in design, relying on a single follow-up assessment rather than tracking patients over time, and it used subjective scales rather than objective measures such as polysomnography or actigraphy to capture sleep. The sample of 186 patients, while adequate for the statistical analyses performed, was drawn from a single clinical setting, and the subgroup analyses, though suggestive, involved smaller numbers and carry a risk of false-positive findings. The researchers themselves state that these exploratory findings require validation in prospective studies using objective sleep assessments. Until such studies are done, the interaction should be viewed as a hypothesis-generating signal rather than a settled fact.

Even with those caveats, the study opens a window onto an underappreciated dimension of cardiac recovery. The months after a stent procedure are a period of profound physiological and psychological recalibration, and the interplay between the drugs we give and the minds we treat may shape how well patients sleep, and by extension how well they heal. If a lipophilic β-blocker amplifies the sleep-destroying power of anxiety in precisely those patients who are otherwise healthiest, then the paradox the Chinese team describes is more than a statistical curiosity. It is a reminder that in modern cardiology, the heart and the brain are never treated in isolation, and that the prescription pad and the psychiatric interview may need to be read side by side.

Subject of Research: Interaction between β-blocker use and anxiety in early post-procedural sleep disorders after complete percutaneous coronary revascularization

Article Title: β-Blockers, anxiety, and sleep: an analysis of interactions in early sleep disorders following percutaneous complete revascularization

Article References: Zhang, H., Li, D., & Zhang, X. (2026). β-Blockers, anxiety, and sleep: an analysis of interactions in early sleep disorders following percutaneous complete revascularization. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08659-w

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08659-w

Keywords: β-blockers, anxiety, sleep quality, coronary heart disease, percutaneous coronary intervention, revascularization, metoprolol, insulin resistance, HOMA-IR, Gensini score, psychopharmacology, BMC Psychiatry

The study, led by Jorge Dahdal of Amsterdam University Medical Center together with colleagues from Turku University Hospital in Finland and several European institutions, is notable for its technical rigor. Every patient underwent both coronary computed tomography angiography (CCTA) and positron emission tomography (PET) myocardial perfusion imaging using oxygen-15 labeled water, a tracer considered the gold standard for quantifying absolute blood flow to the heart muscle. Rather than relying on the subjective, visual assessments that have long dominated clinical practice, the team deployed an FDA-cleared AI software platform to measure plaque volume in every coronary segment larger than 1.5 millimeters in diameter. The software distinguishes atherosclerotic tissue from epicardial fat and the vessel lumen, sums the volume of every lesion, and normalizes that total to the overall volume of the vessel tree. The resulting metric, percent atheroma volume or PAV, expresses the proportion of the coronary artery wall occupied by plaque — a continuous, quantitative measure of how much atherosclerosis a patient carries.

On the functional side, the researchers quantified hyperemic myocardial blood flow, or hMBF, the rate at which blood reaches the heart muscle when it is pushed to its maximum demand. Patients abstained from caffeine for at least 24 hours before their scans, and pharmacologic hyperemia was induced with intravenous adenosine at 140 micrograms per kilogram per minute. Dedicated software packages at the two centers, CardiacVUer in Amsterdam and Carimas in Turku, generated parametric flow maps across the standard 17-segment model of the left ventricle. The team defined regional hMBF as the lowest mean flow across two contiguous myocardial segments, a deliberately conservative measure that captures focal flow reductions without diluting them in a whole-heart average. Perfusion was classified as normal above 2.3 milliliters per minute per gram and graded as mildly, moderately, or severely reduced below that threshold. The two measures were, unsurprisingly, related: patients with more plaque tended to have lower hyperemic flow, with a moderate inverse correlation (Spearman’s rho of -0.47).

The cohort itself reflected the messy reality of real-world cardiology. Between 2007 and 2016, symptomatic patients with suspected coronary artery disease and no prior cardiac history were enrolled at two centers with different imaging philosophies. In Amsterdam, combined CCTA and PET perfusion imaging was performed routinely in all referred patients, while in Turku, PET was performed selectively when CCTA suggested obstructive disease. The patients had a mean age of 62 years, 54 percent were male, 58 percent had hypertension, and 18 percent had diabetes. Median percent atheroma volume was 7.9 percent, with nearly 28 percent of patients showing extensive plaque burden, and impaired regional perfusion was detected in roughly half the cohort. Twenty percent of patients underwent early revascularization — stenting or bypass surgery within six months of imaging — a fact that would prove central to interpreting the results.

Over a median follow-up of 7.1 years, extending as far as 13.3 years, 185 patients — 13.4 percent of the cohort — experienced the composite outcome of all-cause death, non-fatal myocardial infarction, or unstable angina. Deaths accounted for just over half of these events, followed by heart attacks and unstable angina. The cumulative event rate climbed from 5.2 percent at three years to 9.5 percent at six years and 12.1 percent at nine years. Patients who suffered events had dramatically higher plaque burden than those who did not — a median PAV of 15.4 percent versus 7.0 percent — and significantly lower regional blood flow, 1.85 versus 2.38 milliliters per minute per gram. Kaplan-Meier survival curves showed a stepwise deterioration in event-free survival with each increasing stage of plaque burden and each grade of perfusion impairment, a visual gradient that foreshadowed the statistical findings to come.

The heart of the analysis lay in a series of multivariable Cox regression models that pitted the two imaging metrics against each other while adjusting for age, sex, hypertension, diabetes, and early revascularization. When each measure was considered alone, both predicted events at every timepoint. But when both were entered into the same model — a head-to-head test of independent prognostic value — a clear division of labor emerged. Each 1 percent increase in percent atheroma volume raised the hazard of an event by roughly 3.5 to 4.7 percent at all three timepoints, with adjusted hazard ratios of 1.047, 1.035, and 1.036 at three, six, and nine years respectively, all highly statistically significant. Regional hMBF, by contrast, remained independently predictive at three years (a hazard ratio of 1.050 per 0.1 milliliter per minute per gram decrease, p = 0.004) and six years (1.028, p = 0.024), but the association weakened to statistical insignificance by nine years (1.020, p = 0.063).

Why would ischemia’s predictive power fade while plaque burden’s endured? The answer, the researchers argue, lies largely in what happened after the scans were taken. Interaction analysis revealed that early revascularization significantly modified the prognostic associations of both metrics, suggesting that opening blocked arteries changes the natural history that the imaging had captured. When the team repeated the analysis after excluding the 281 patients who underwent early revascularization, the picture transformed: both plaque burden and regional blood flow were significantly associated with outcomes at all three timepoints, including nine years. In other words, untreated ischemia retains its full prognostic force over the long term, but once clinicians relieve it with stents or bypass grafts, the flow measurement no longer reflects the risk it once did — the risk has been, at least partly, defused. Plaque burden, by contrast, is not so easily erased; it represents the cumulative atherosclerotic substrate that continues to generate risk regardless of any single intervention.

These findings land in the middle of an ongoing and often heated debate about the value of ischemia detection. Landmark randomized trials such as COURAGE and ISCHEMIA showed that revascularization guided by ischemia, while effective at relieving symptoms, does not reliably improve hard clinical outcomes compared with guideline-directed medical therapy in stable coronary disease. Skeptics have used those results to question whether ischemia imaging is worth the cost and radiation. But the authors of the new study point out that those trials relied on earlier-generation perfusion techniques or even non-imaging exercise testing, which may have failed to fully characterize the burden and complexity of ischemia. Quantitative PET perfusion imaging offers a continuous, precise measurement rather than a binary yes-or-no answer, and observational studies have consistently shown it adds prognostic information beyond anatomy. This study is among the first to demonstrate that PET-derived ischemia remains independently predictive even when integrated with AI-based quantitative plaque analysis, a technique rapidly entering clinical practice.

The clinical implications are correspondingly two-pronged. Recent scientific statements from the American College of Cardiology and the American Heart Association now endorse AI-based quantitative plaque analysis to enhance risk assessment and guide preventive therapy in patients with plaque visible on CCTA. The new data suggest that percent atheroma volume may be particularly valuable for long-term risk stratification, especially in patients with non-obstructive disease whose anatomic risk is otherwise underestimated, potentially justifying more intensive lipid-lowering and preventive strategies. Regional hyperemic blood flow, meanwhile, identifies patients at elevated near-term risk and may inform symptom-directed management and closer short-term follow-up. The two measurements, in effect, answer different questions: plaque burden describes the size of the reservoir of future risk, while ischemia signals how much of that risk is about to be expressed. Staging frameworks linking plaque volume to preventive treatment targets have been proposed, though optimal thresholds remain under active investigation.

The authors are careful to acknowledge the study’s limitations. As a retrospective observational analysis, it lacked comprehensive data on post-imaging medical therapy, used all-cause rather than cardiovascular-specific mortality, and involved different scanner hardware across the two centers. The findings pertain specifically to absolute flow measurements from oxygen-15 water PET and may not extend directly to flow reserve indices or other tracers. Residual confounding is an inherent risk, particularly around the selection of patients for early revascularization. Yet the consistency of the results across alternative plaque and perfusion metrics, different revascularization definitions, and both imaging protocols strengthens the central conclusion: anatomy and function are not rivals but complementary windows onto coronary disease, each with its own temporal signature. For a field still deciding how best to deploy its increasingly powerful imaging arsenal, that temporal map — plaque for the long game, ischemia for the near term — may prove one of the most actionable findings yet.

Subject of Research: Time-dependent prognostic value of coronary plaque burden and hyperemic myocardial blood flow in suspected coronary artery disease

Article Title: Time-dependent prognostic value of coronary plaque burden and hyperemic myocardial blood flow

Article References: Time-dependent prognostic value of coronary plaque burden and hyperemic myocardial blood flow. (n.d.). https://doi.org/10.1007/s00259-026-08135-3

Image Credits: AI Generated

DOI: 10.1007/s00259-026-08135-3

Keywords: coronary artery disease, CCTA, PET imaging, plaque burden, myocardial ischemia, percent atheroma volume, hyperemic myocardial blood flow, risk stratification, artificial intelligence, revascularization, cardiovascular outcomes, nuclear medicine

The study, published in the European Journal of Nuclear Medicine and Molecular Imaging, was led by Rong Wang of Gansu Provincial Hospital in Lanzhou and Wei Dong of Beijing Anzhen Hospital, Capital Medical University. The researchers enrolled 174 patients who had undergone percutaneous coronary intervention, or PCI, the umbrella term for stenting and related catheter-based procedures. Crucially, every participant had angiographically confirmed complete revascularization, meaning their large epicardial arteries showed no significant residual blockages. In other words, by conventional measures, these hearts had been fixed. The question was whether a deeper look would reveal lingering trouble.

The deeper look came from a technology called dynamic SPECT, abbreviated D-SPECT, which uses fast cadmium-zinc-telluride detectors to track a radioactive tracer moving through the heart muscle in real time. Traditional perfusion scans capture a single static snapshot of blood distribution, revealing only whether some regions of the heart look dimmer than others. Dynamic imaging goes further: by measuring how quickly the tracer arrives and washes out, clinicians can calculate absolute blood flow in milliliters per gram per minute, both at rest and during pharmacological stress, when a drug dilates the vessels to simulate exercise. The ratio of stress flow to rest flow yields the myocardial flow reserve, or MFR — a numerical gauge of how much extra blood delivery the heart can summon when demand rises.

A healthy heart can multiply its resting blood flow several-fold under stress. When that reserve falls below 2.0, it signals that the coronary microvasculature — the dense network of arterioles and capillaries too small to appear on any angiogram — cannot dilate properly. The researchers defined coronary microvascular disease, or CMD, as a global or territorial MFR below this threshold in the absence of any epicardial stenosis greater than 50 percent. This definition matters because microvascular dysfunction is increasingly recognized as a disease entity in its own right, one that causes ischemia, drives symptoms, and worsens outcomes even when the conduit arteries are wide open. Prior work has linked it to adverse remodeling of the heart muscle, diastolic dysfunction, and elevated risk in patients with diabetes and prior infarction.

The results were striking. Over a median follow-up of 12 months, during which some patients were followed for as long as 21 months, 42 of the 174 patients — 24.1 percent — suffered a major adverse cardiac event. The composite endpoint was deliberately broad, encompassing all-cause death, myocardial infarction, unscheduled coronary revascularization, stroke, hospitalization for heart failure, and rehospitalization for angina. When the investigators split the cohort by microvascular status, the difference was unmistakable: patients with CMD experienced significantly higher event rates, a separation visible on survival curves with a log-rank statistic of 11.375 and a p-value of 0.001.

What makes the finding clinically persuasive is that it survived rigorous statistical scrutiny. The team applied multivariable Cox regression, adjusting for traditional cardiovascular risk factors and for abnormal findings on conventional myocardial perfusion imaging. Even after accounting for these established predictors, CMD remained an independent predictor of adverse outcomes, carrying a hazard ratio of 2.46 — meaning patients with impaired flow reserve faced roughly two and a half times the risk of a major event compared with those whose microvessels functioned normally. The 95 percent confidence interval ranged from 1.27 to 4.76, and the p-value of 0.007 indicated the association was unlikely to be chance. Notably, the association held consistently across all prespecified patient subgroups.

The study also delivered a technical refinement with practical implications. Rather than relying solely on a single global MFR value averaged over the whole left ventricle, the researchers analyzed regional MFR — flow reserve measured separately in the territories supplied by each of the major coronary arteries. Statistical reclassification analyses quantified how much this regional approach added. The net reclassification improvement, or NRI, was 0.524, and the integrated discrimination improvement, or IDI, was 0.036, both statistically significant. In plain terms, looking at the heart territory by territory reclassified a meaningful fraction of patients into more accurate risk categories and improved the model’s ability to distinguish those who would have events from those who would not. A globally normal flow reserve can mask a severely diseased single territory, and the regional analysis catches what the average conceals.

The implications extend beyond the cardiology ward. Coronary microvascular dysfunction has long been difficult to assess outside specialized centers, historically requiring invasive catheter-based measurements such as the index of microcirculatory resistance, which involves threading a pressure-temperature sensor wire into the coronary artery. Noninvasive quantification with dynamic CZT-based SPECT offers a way to screen patients after PCI without additional catheterization. If confirmed, the approach could change post-procedural care: patients flagged with low flow reserve might be candidates for intensified medical therapy targeting the microcirculation — including aggressive risk-factor control, antiplatelet and lipid-lowering regimens, and emerging microvascular-directed treatments — while those with robust reserves might be spared unnecessary interventions and anxiety.

The authors are careful to frame their conclusions appropriately. This was a pilot study, exploratory in design, with a relatively modest sample size and a median follow-up of only one year — short by the standards of cardiovascular outcomes research. The researchers themselves call for validation in larger multi-center studies with longer follow-up and direct comparisons against invasive reference measurements. The cohort was drawn from two Chinese hospitals, Gansu Provincial Hospital and Beijing Anzhen Hospital, and whether the findings generalize to other populations remains to be demonstrated. Ethical approval was obtained from both institutions, and the work was funded by the National Natural Science Foundation of China along with provincial and municipal research programs.

Even with those caveats, the study adds an important piece to one of cardiology’s most persistent puzzles: why symptoms and events persist after anatomically successful revascularization. It reinforces a conceptual shift that has been gathering momentum in the field — that the coronary circulation must be evaluated as a whole, from the epicardial conduits down to the microscopic vessels where oxygen actually exchanges with heart muscle. For the roughly one in four patients in this cohort destined for a major cardiac event despite complete stenting, a 20-minute dynamic nuclear scan may soon offer something that angiography never could: a genuine look at the plumbing that matters most, and a head start on preventing the next crisis before it strikes.

Subject of Research: D-SPECT-derived myocardial flow reserve for detecting coronary microvascular disease and predicting outcomes after complete revascularization

Article Title: Prognostic value of D-SPECT-derived myocardial flow reserve in detecting coronary microvascular disease and predicting outcomes after complete revascularization: a two-center pilot study

Article References: Wang, R., Bai, J., Xie, P., Wang, H., Wang, X., Gao, Z., Chen, Y., Mi, H., & Dong, W. (2026). Prognostic value of D-SPECT-derived myocardial flow reserve in detecting coronary microvascular disease and predicting outcomes after complete revascularization: a two-center pilot study. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08162-0

Image Credits: AI Generated

DOI: 10.1007/s00259-026-08162-0

Keywords: D-SPECT, myocardial flow reserve, coronary microvascular disease, percutaneous coronary intervention, major adverse cardiac events, nuclear cardiology, SPECT imaging, coronary microcirculation, prognosis, revascularization, cardiac imaging, Prognostic

The study drew on claims data from AOK – Die Gesundheitskasse, one of Germany’s largest statutory health insurers, allowing the investigators to identify 99,415 patients hospitalized for peripheral arterial disease between January 1, 2019 and December 31, 2020. This scale matters. Most previous studies of mental health in vascular disease have been small, single-center efforts that often conflated depression, anxiety, and cognitive impairment into a single category of psychological comorbidity. By contrast, the German dataset offered the statistical power to compare these disorders head to head, using multivariable-adjusted analyses and Cox regression models to account for age, sex, disease severity, and other cardiovascular risk factors.

The headline finding is striking in its simplicity: 47 percent of patients hospitalized for peripheral arterial disease had at least one of the three mental disorders. That figure alone should reshape how vascular teams think about their patient population. Patients with these conditions were more frequently female, presented with more advanced stages of arterial disease, and carried a heavier overall cardiovascular risk profile. In other words, the sickest patients with the most compromised circulation were also the ones most likely to be living with a mental health diagnosis, a convergence that sets the stage for the treatment disparities the study went on to document.

When the researchers disaggregated the three conditions, the picture became far more nuanced than the conventional wisdom suggests. Dementia stood out as the condition associated with the most pronounced disparities in care. Patients with dementia underwent revascularization, the procedures that restore blood flow to blocked leg arteries, at substantially lower rates than their peers. They also received statin therapy, the cornerstone guideline-recommended cholesterol-lowering treatment for atherosclerotic disease, far less often, despite presenting with more advanced disease at the time of hospitalization. This pattern of undertreatment in the face of greater need represents what the authors describe as an important and underrecognized gap in vascular care.

The prognostic consequences of dementia were equally dramatic. In the Cox regression models, dementia emerged as a strong independent predictor of all-cause mortality, with hazard ratios ranging from 1.57 to 1.62, meaning that patients with dementia faced a roughly 60 percent higher risk of death during follow-up compared with otherwise similar patients. Dementia also predicted the composite outcome of amputation and/or death, with hazard ratios between 1.49 and 1.56, and both associations were highly statistically significant. For a condition that is often treated as a background characteristic rather than a clinical variable, these numbers place dementia firmly in the category of major prognostic factors in peripheral arterial disease.

Depression, by contrast, told a quieter story. Although depression was the most prevalent of the three conditions and has been the focus of most prior research linking mental health to vascular outcomes, its association with adverse outcomes in this cohort was only modest after full statistical adjustment. Anxiety disorders fared even worse as prognostic markers, showing no consistent association with increased risk once the models accounted for other clinical variables. The authors conclude that mental disorders in peripheral arterial disease are not prognostically homogeneous, a phrase that carries real weight for trial designers, guideline writers, and clinicians who have traditionally bundled these conditions together under a single comorbidity flag.

Why might dementia exert such a disproportionate influence? The study itself points toward a combination of biological and systems-level mechanisms. On the biological side, dementia and peripheral arterial disease share deep vascular roots: atherosclerosis, endothelial dysfunction, and chronic inflammation injure both the brain and the limbs, and prior nationwide studies have shown that the risk of dementia differs across cardiovascular diseases and dementia subtypes. On the systems side, cognitive impairment complicates every step of vascular care. Patients with dementia may report claudication symptoms late or not at all, may struggle to adhere to complex medication regimens including statins and antiplatelet agents, and may be deemed poor candidates for revascularization by clinicians weighing procedural risk against limited expected benefit. Previous work in vascular surgery populations has documented that cognitive impairment is common and frequently undiagnosed in older patients undergoing vascular procedures, and that patients with dementia undergoing major limb amputation have particularly poor outcomes.

The treatment disparities documented in the study echo a pattern seen in other cardiovascular fields. Research on stroke care has shown that dementia is associated with poorer quality of care and worse outcomes after stroke, and the new findings suggest that a similar dynamic operates in the peripheral circulation. Whether the lower rates of revascularization and statin therapy in patients with dementia reflect explicit clinical judgment, implicit bias, communication barriers, or patient and family preferences cannot be determined from claims data alone. But the result is a vulnerable population that receives less of the therapy that guidelines recommend for everyone with atherosclerotic disease, while simultaneously bearing the highest risk of dying or losing a limb.

The study’s methodology deserves attention as well. Claims data offer unmatched scale and the ability to capture real-world treatment patterns across an entire country, but they also carry limitations inherent to administrative records. Diagnoses depend on coding practices, the severity of dementia and depression cannot be graded, and over-the-counter medications and care delivered outside the hospital may escape detection. The authors also note that the data are held by the Wissenschaftliches Institut der AOK in Berlin and are not publicly available, with access governed by contractual and data protection regulations. The work was funded as part of the LINCARE project by the Innovation Fund of the Federal Joint Committee, the German body that steers innovation in statutory health care.

For clinicians, the practical message is that screening for cognitive impairment should become as routine in vascular clinics as measuring the ankle-brachial index. For researchers, the findings argue for disaggregating mental health comorbidities in future trials and registries rather than collapsing them into a single variable. And for health systems, the study highlights a population in which coordinated care, involving vascular specialists, geriatricians, psychiatrists, and primary care physicians working together, could plausibly change outcomes that are currently among the worst in cardiovascular medicine. As the authors put it, dementia identifies a particularly vulnerable and undertreated peripheral arterial disease population, and recognizing that distinction is the first step toward closing a gap in care that has remained invisible for far too long.

Subject of Research: The differential impact of depression, anxiety, and dementia on prognosis and treatment patterns in patients hospitalized for peripheral arterial disease

Article Title: Not all mental disorders matter equally in peripheral arterial disease: Dementia drives prognosis and care disparities

Article References: Not all mental disorders matter equally in peripheral arterial disease: Dementia drives prognosis and care disparities. (n.d.). https://doi.org/10.1007/s00392-026-03027-w

Image Credits: AI Generated

DOI: 10.1007/s00392-026-03027-w

Keywords: peripheral arterial disease, dementia, depression, anxiety disorders, revascularization, statin therapy, amputation, mortality, claims data, health care disparities, cardiovascular risk, vascular care

Kawasaki disease is the leading cause of acquired heart disease in children in many parts of the world. The condition, whose exact trigger remains uncertain, produces widespread inflammation of blood vessels, and the coronary arteries are its most vulnerable targets. In a subset of patients, the vessel walls weaken so profoundly that giant coronary artery aneurysms form, measuring far beyond normal arterial dimensions. These aneurysms are not merely cosmetic distortions. Blood stagnates inside them, clots form, and over time the inflamed vessel walls can scar and narrow until the artery closes completely. The result is a cruel paradox: segments of artery that are abnormally wide in one place may be critically obstructed in another, starving the heart muscle of oxygen and setting the stage for myocardial infarction even in childhood.

For this patient, the disease had run an aggressive course. Echocardiography and coronary computed tomography angiography documented giant aneurysms involving both the left and right coronary systems, with occlusive lesions that compromised flow to the heart muscle. Medical therapy alone could not restore perfusion, so the surgical team turned to coronary artery bypass grafting, the standard revascularization strategy for severe Kawasaki-related coronary disease. Surgeons used arterial grafts, including the internal mammary arteries, to create new channels from the aorta to the coronary arteries beyond the blockages. Bypass surgery in children with Kawasaki disease is technically demanding: the target vessels are small, the aneurysmal walls are diseased, and the patient will need these grafts to function for decades. The initial operation succeeded, and the boy recovered with his heart muscle once again receiving blood through the reconstructed pathways.

The danger, however, had not passed. Roughly a year after surgery, surveillance revealed stenosis at the anastomosis, the delicate hand-sewn junction where the right internal mammary artery graft had been connected to the right coronary artery. Anastomotic stenosis is a recognized complication of bypass grafting, arising from scar tissue formation, intimal thickening, or technical factors at the connection site. In adults, such narrowing is often addressed with repeat surgery or percutaneous coronary intervention, the catheter-based family of techniques that includes balloon angioplasty and stent placement. In children, the evidence base is thin. Pediatric coronary arteries are small, the graft anatomy is complex, and the long-term behavior of coronary stents in growing bodies remains incompletely understood. Reports on managing post-CABG anastomotic stenosis in children are so limited that each documented case carries outsized educational value.

The Shanghai team elected to attempt percutaneous salvage. Under angiographic guidance, clinicians advanced a catheter to the narrowed segment, confirmed the severity and extent of the stenosis, and deployed a stent to scaffold the vessel open. Intravascular ultrasound, an imaging tool that provides a cross-sectional view from inside the artery, supports such procedures by characterizing the lesion and verifying that the stent is fully expanded and well apposed to the vessel wall. The procedure restored flow through the right internal mammary artery graft, re-establishing perfusion to the territory it was built to protect. For a patient whose native coronary arteries were already devastated, preserving the patency of even one graft can make the difference between a functioning heart and progressive ischemic damage.

The technical logic of the intervention rewards close attention. A bypass graft is only as good as its weakest point, and the anastomosis is inherently the most vulnerable: it is a junction between two vessels of different calibers and compliance, joined by suture in tissue that is actively remodeling. When scar narrows that junction, the entire graft is throttled regardless of how healthy its length may be. A stent acts as an internal splint, mechanically resisting the inward recoil of scarred tissue. In this case, the stent was positioned to hold open the outflow of the arterial graft into the right coronary artery, converting a failing surgical connection into a widely patent conduit. Follow-up imaging confirmed the result, and myocardial perfusion imaging performed six months after the procedure showed only mild reversible ischemia at the apex and apical inferior wall, with tracer uptake replenishing at rest, an encouraging functional signature of restored blood supply.

Beyond the procedural success, the case underscores a principle that pediatric cardiologists emphasize repeatedly: Kawasaki disease is not an acute illness that ends when the fever resolves. Children with giant coronary aneurysms require lifelong surveillance, because complications can emerge years or decades after the initial inflammation. Aneurysms can thrombose, calcify, and stenose silently. Bypass grafts, which behave in children much as they do in adults but must endure far longer, can fail gradually or suddenly. The stenosis in this patient appeared a full year after CABG, a delay that illustrates why serial echocardiography, coronary imaging, and functional assessment such as stress myocardial perfusion imaging are indispensable in this population. A single reassuring scan is never a discharge from care.

The report also highlights the multidisciplinary nature of modern management for these patients. Caring for a child with Kawasaki-related giant aneurysms draws on pediatric rheumatology for control of inflammation, noninvasive cardiology for imaging and functional assessment, cardiac surgery for revascularization, and interventional cardiology for catheter-based rescue. Each decision, from the choice of antithrombotic therapy to the selection of graft targets to the timing of intervention on a stenotic anastomosis, must be individualized to anatomy that is often unlike anything seen in adult practice. The authors frame their experience as a guide to such individualized management, noting that percutaneous coronary intervention can be an effective therapeutic option in selected pediatric cases, even in the challenging setting of a post-surgical graft complication.

For the broader clinical community, the message is twofold. First, stent implantation deserves consideration as a salvage strategy when a bypass graft fails in a child, provided the anatomy is suitable and an experienced interventional team is available; repeat sternotomy in a patient with diseased, aneurysmal coronaries carries substantial risk, and a catheter-based solution may offer a safer path to restored perfusion. Second, the case is a reminder that the frontier of pediatric cardiology increasingly involves adults-in-the-making: children who survived acute Kawasaki disease in the era of modern diagnosis now live for decades with coronary anatomy that demands the full toolkit of cardiovascular medicine. As the surviving cohort grows, so too will the need for evidence on how best to monitor, maintain, and when necessary rescue the surgical and catheter-based repairs that keep their hearts supplied with blood. This single patient’s successful stent rescue adds a concrete data point to a sparse literature, and it offers reassurance that when a child’s bypass graft begins to fail, the interventional catheter lab may hold the answer.

Subject of Research: Stent implantation to treat anastomotic stenosis of a coronary bypass graft after CABG in a child with Kawasaki disease

Article Title: Salvage stent implantation for anastomotic stenosis after coronary artery bypass grafting in Kawasaki disease: a case report

Article References: Zheng, Y., Zhao, L., Dai, G., Chu, C., Zhao, Q., Wang, F., Lin, Y., He, L., & Liu, F. (2026). Salvage stent implantation for anastomotic stenosis after coronary artery bypass grafting in Kawasaki disease: a case report. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07668-8

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07668-8

Keywords: Kawasaki disease, coronary artery aneurysms, coronary artery bypass grafting, percutaneous coronary intervention, stent implantation, anastomotic stenosis, pediatric cardiology, internal mammary artery graft, myocardial perfusion imaging, revascularization, restenosis, children's heart disease

The research, led by Tej Jolly, Arnav Garcha, and Noelia Grande Gutiérrez of Carnegie Mellon University, tackled a stubborn methodological problem. Patient studies have long hinted that the health of the coronary microvasculature, the dense network of arterioles and capillaries downstream of the major arteries, influences both FFR and CFR. But in real patients, microvascular status is tangled up with anatomical variation: every artery has a different lesion length, severity, and branching pattern, making it nearly impossible to isolate what the microcirculation alone is doing. Computational studies have tried to fill the gap, yet most either fix the downstream resistance at a single value or sample only a narrow range of microvascular states, and patient-specific models confound geometry with physiology.

To break that confounding, the team built a multiscale modeling framework that couples three-dimensional computational fluid dynamics of the epicardial coronary arteries with a lumped-parameter network representing the microvascular bed. The three-dimensional component solves the incompressible Navier–Stokes equations over unstructured tetrahedral meshes averaging 3.3 million elements, with boundary-layer refinement near the walls and local refinement around stenoses. Blood was treated as a Newtonian fluid, a reasonable approximation given that simulated shear rates exceeded 100 per second, and flow was assumed laminar, with Reynolds numbers averaging around 200 and peaking at 967 under the most severe stenosis and highest flow. Transient simulations ran for four cardiac cycles at a heart rate of 70 beats per minute, with periodic convergence defined as less than one percent change in outlet pressure and flow between cycles.

The anatomical foundation was equally deliberate. The researchers generated a baseline left coronary artery model using population-mean values for branch diameters, bifurcation angles, and segment lengths drawn from a computed tomography angiography study of 300 adults with zero coronary calcium scores. Onto this fixed skeleton they imposed nine plaque configurations, varying lesion location between the left anterior descending artery and the left circumflex, lesion length between a focal 1.2 centimeters and a diffuse 2.5 centimeters, and stenosis severity across zero, 45, and 60 percent diameter reduction. The 45 percent severity was chosen after exploratory sweeps showed that FFR most often crossed its clinical threshold of 0.8 between 40 and 50 percent narrowing, precisely the borderline zone where diagnostic uncertainty is greatest. Stenoses were modeled as asymmetric constrictions to mimic the eccentric plaque morphology commonly seen in atherosclerosis.

Each of the nine geometries was then run under four hyperemic microvascular resistance states, produced by scaling the microvascular resistor in the lumped network to represent total coronary resistance equal to 24, 43, 62, and 81 percent of its resting value. The baseline of 24 percent reflects the maximum resistance reduction achievable with intravenous adenosine, the hyperemic agent used in clinical FFR measurement, while the elevated states span progressively impaired vasodilation. The resulting hyperemic microvascular resistance values ranged from 1.3 to 8.1 millimeters of mercury per centimeter per second, bracketing the clinical dysfunction threshold of 2.5 and matching pathologically observed ranges. Nine additional resting simulations brought the total to 45, and the simulated cases were verified against a retrospective observational cohort of 299 patients, occupying the same joint distributions of stenotic burden, microvascular resistance, and index values as the clinical data.

The headline finding is strikingly clean: for geometrically identical lesions, raising microvascular resistance increased FFR and decreased CFR. Across all 36 hyperemic simulations, the correlation between microvascular resistance and FFR was strong and positive, while the correlation with CFR was very strong and negative. The mechanism follows directly from the physics. Higher downstream resistance throttles hyperemic flow, and since the pressure drop across a stenosis scales with flow, a throttled flow shrinks the trans-stenotic pressure gradient, making FFR appear more reassuring even as the tissue receives less blood. Meanwhile, the ratio of hyperemic to resting distal velocity collapses toward unity, dragging CFR downward. In short, coronary flow in these models was governed primarily by the microcirculation rather than by the epicardial blockage itself, with flow bands overlapping broadly across lesions of different severities when stratified by stenosis.

The threshold analysis carries the most clinical weight. Because treatment decisions hinge on binary cutoffs—FFR of 0.8 and CFR of 2—the team fitted regression models within narrow bands around those values. Near the FFR threshold, the standardized coefficients for microvascular resistance and hyperemic stenosis resistance were comparable in magnitude and both highly significant, with models explaining over 90 percent of the variance. This means that near-threshold FFR readings reflect both the epicardial lesion and the microvascular state, so a shift across the cutoff cannot be uniquely attributed to plaque severity. Near the CFR threshold, by contrast, microvascular resistance dominated, consistent with CFR’s role as the gold standard for microvascular function. The response was also nonlinear: the transition from healthy to the first impaired microvascular state produced far larger changes in flow and FFR than transitions deeper into dysfunction, with sensitivity to microvascular resistance dropping by roughly 77 percent for FFR and 71 percent for CFR as both indices approached a plateau once hyperemic flow was already severely limited.

Perhaps most provocatively, the simulations reproduced both modes of FFR–CFR discordance in identical anatomies purely by varying microvascular resistance. The same plaque could land in the preserved-FFR, reduced-CFR quadrant or the reduced-FFR, preserved-CFR quadrant depending on the microvascular state alone, and preserved FFR with reduced CFR was consistently associated with higher microvascular resistance. Notably, lesion length showed no association with the direction of discordance in a Fisher’s exact test, suggesting that the focal-versus-diffuse distinction, often invoked to explain index disagreements, may be an inadequate surrogate for physiological state. The study also found that elevated microvascular resistance expanded the arterial wall area exposed to low wall shear stress at the LAD–LCx bifurcation, an atherogenic condition, and shrank areas of high shear stress linked to cap thinning and plaque rupture, with the bifurcation effects persisting even after controlling for bulk flow rate.

The implications reach from the catheterization lab to the computational pipeline. Clinically, lesions with FFR at or below 0.50 remain significant regardless of microvascular status, but when microvascular resistance is elevated, an FFR above 0.8 can coexist with a pathologically low CFR, and severe microvascular disease can push CFR below threshold even with no stenosis at all and an FFR near 1. In such cases, flow-oriented evidence from perfusion imaging or CFR itself should carry more weight. Conversely, when microvascular resistance is low and flow runs high, pressure-based indices can be penalized, and flow-normalized metrics such as hyperemic stenosis resistance become especially informative. For the growing field of CT-derived FFR, the message is that distal boundary conditions are not mere numerical settings—they encode microvascular health, and uncertainty in them propagates directly into predicted indices. The authors argue that hyperemic microvascular resistance should be reported routinely alongside FFR and CFR, both in the clinic and in computational studies, so that geometric effects are not mistaken for physiological ones and so that cross-study comparisons become reproducible. Future work will extend the framework to patient-specific coronary trees, compliant walls, branch-specific and time-varying microvascular parameterizations, and prospective validation against simultaneous invasive pressure-flow measurements and perfusion imaging.

Subject of Research: The effect of hyperemic microvascular resistance on coronary hemodynamic diagnostic indices such as FFR and CFR, investigated through multiscale computational fluid dynamics simulation.

Article Title: Impact of Microvascular Resistance on Coronary Hemodynamic Diagnostic Indices: A Multiscale Simulation Study

Article References: Impact of Microvascular Resistance on Coronary Hemodynamic Diagnostic Indices: A Multiscale Simulation Study. (n.d.). https://doi.org/10.1007/s10439-026-04378-1

Image Credits: AI Generated

DOI: 10.1007/s10439-026-04378-1

Keywords: coronary artery disease, fractional flow reserve, coronary flow reserve, microvascular resistance, computational fluid dynamics, coronary hemodynamics, lumped-parameter network, stenosis, wall shear stress, revascularization, CT-FFR, cardiovascular modeling